Compare · NMRA vs RVMD
NMRA vs RVMD
Side-by-side comparison of Neumora Therapeutics Inc. (NMRA) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NMRA and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $44.44B, about 189.2x NMRA ($234.9M).
- Over the past year, NMRA is down 25.6% and RVMD is up 405.9% - RVMD leads by 431.5 points.
- RVMD has been more active in the news (12 items in the past 4 weeks vs 11 for NMRA).
- RVMD has more recent analyst coverage (25 ratings vs 23 for NMRA).
- Company
- Neumora Therapeutics Inc.
- Revolution Medicines Inc.
- Price
- $1.25-3.85%
- $207.28-1.34%
- Market cap
- $234.9M
- $44.44B
- 1M return
- -23.31%
- +1.03%
- 1Y return
- -25.60%
- +405.93%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- 2020
- News (4w)
- 11
- 12
- Recent ratings
- 23
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest NMRA
- Officer Aurora Daljit Singh exercised 176,060 shares at a strike of $0.72 and sold $269,967 worth of shares (176,060 units at $1.53) (SEC Form 4)
- SEC Form 4 filed by Officer Berns Paul L
- SEC Form 4 filed by Officer Duncan Jason
- SEC Form 4 filed by Officer Milligan Michael Lee
- SEC Form 4 filed by President & CEO Pinto Joshua
- SEC Form 144 filed by Neumora Therapeutics Inc.
- SEC Form 144 filed by Neumora Therapeutics Inc.
- Officer Aurora Daljit Singh exercised 243,753 shares at a strike of $0.72 and sold $431,674 worth of shares (277,773 units at $1.55), decreasing direct ownership by 41% to 48,750 units (SEC Form 4)
- SEC Form 144 filed by Neumora Therapeutics Inc.
- SEC Form 144 filed by Neumora Therapeutics Inc.
Latest RVMD
- New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
- Director Kim Lorence H. sold $11,381,288 worth of shares (56,000 units at $203.24) as part of a pre-agreed trading plan (SEC Form 4)
- Revolution Medicines Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- FDA Approval for RASONQUE issued to REVOLUTION MEDICINES INC
- Bloomberg 500 (B500) Index Adds Ten Securities Following September Reconstitution
- Revolution Medicines Inc. filed SEC Form 8-K: Other Events
- U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
- General Counsel Cislini Jeff exercised 56,280 shares at a strike of $20.00 and sold $11,904,247 worth of shares (56,894 units at $209.24) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 55,907 units (SEC Form 4)
- Officer Goldsmith Mark A exercised 80,000 shares at a strike of $4.73 and sold $17,991,107 worth of shares (86,000 units at $209.20) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Revolution Medicines Inc.